Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

Bryan A. Ward, J. Christopher Gorski, David R. Jones, Stephen D. Hall, David A. Flockhart and Zeruesenay Desta
Journal of Pharmacology and Experimental Therapeutics July 2003, 306 (1) 287-300; DOI: https://doi.org/10.1124/jpet.103.049601
Bryan A. Ward
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Christopher Gorski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David R. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen D. Hall
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David A. Flockhart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zeruesenay Desta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 306 no. 1 287-300
DOI 
https://doi.org/10.1124/jpet.103.049601
PubMed 
12676886

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received January 27, 2003
  • Accepted March 28, 2003
  • Published online July 1, 2003.

Article Versions

  • Earlier version (April 3, 2003 - 14:10).
  • You are viewing the most recent version of this article.
Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Bryan A. Ward,
  2. J. Christopher Gorski,
  3. David R. Jones,
  4. Stephen D. Hall,
  5. David A. Flockhart and
  6. Zeruesenay Desta
  1. Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana
  1. Address correspondence to:
    Dr. Zeruesenay Desta, Assistant Professor of Medicine and Pharmacology and Toxicology, Indiana University School of Medicine, Department of Medicine, Division of Clinical Pharmacology, 1001 West 10th Street, WD Myers Bldg., W7123, Indianapolis, IN 46202. E-mail: zdesta{at}iupui.edu
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: April 2003 to March 2021

AbstractFullPdf
Apr 20036044
May 20033041
Jun 2003583895
Jul 20036875101
Aug 2003284333
Sep 2003244146
Oct 2003225044
Nov 2003243226
Dec 2003172621
Jan 2004294936
Feb 2004264828
Mar 2004284132
Apr 2004424621
May 2004587724
Jun 2004688537
Jul 2004636628
Aug 2004697524
Sep 2004376728
Oct 2004359636
Nov 2004209446
Dec 2004336234
Jan 2005197746
Feb 2005209844
Mar 2005265440
Apr 200566444
May 2005165429
Jun 2005335232
Jul 2005266128
Aug 200585818
Sep 2005104929
Oct 2005296035
Nov 2005175433
Dec 2005173932
Jan 2006175231
Feb 2006163929
Mar 2006125141
Apr 2006125744
May 2006113124
Jun 2006143126
Jul 2006163723
Aug 2006204228
Sep 2006232935
Oct 2006434636
Nov 2006163030
Dec 2006273320
Jan 2007114842
Feb 2007163520
Mar 2007334138
Apr 2007364040
May 2007122923
Jun 200782529
Jul 200792923
Aug 2007232627
Sep 2007194025
Oct 2007124841
Nov 2007235438
Dec 200792817
Jan 2008312638
Feb 200832821
Mar 2008214839
Apr 2008193939
May 2008304622
Jun 2008223619
Jul 2008263417
Aug 2008332920
Sep 2008193221
Oct 2008315032
Nov 2008505230
Dec 2008173422
Jan 2009193028
Feb 2009123226
Mar 2009574237
Apr 2009202423
May 2009292823
Jun 2009194135
Jul 2009262216
Aug 2009242935
Sep 2009212519
Oct 2009402617
Nov 200928922
Dec 200928514
Jan 2010323221
Feb 2010293329
Mar 2010512825
Apr 2010432114
May 2010474226
Jun 2010542621
Jul 2010413324
Aug 2010373131
Sep 2010515928
Oct 2010546032
Nov 2010485838
Dec 2010354229
Jan 2011394019
Feb 2011563631
Mar 2011675138
Apr 2011424043
May 2011486947
Jun 2011482531
Jul 2011284033
Aug 2011474737
Sep 2011463424
Oct 2011375333
Nov 2011545235
Dec 2011447330
Jan 2012566933
Feb 2012576646
Mar 2012555626
Apr 2012477036
May 2012416931
Jun 2012425039
Jul 2012344730
Aug 2012513034
Sep 20121025940
Oct 2012906649
Nov 2012557637
Dec 2012475533
Jan 20135914632
Feb 2013609533
Mar 2013814744
Apr 2013715423
May 2013635837
Jun 2013523623
Jul 2013415338
Aug 2013592829
Sep 2013814239
Oct 2013525239
Nov 2013443540
Dec 2013432622
Jan 2014513728
Feb 2014466236
Mar 2014605325
Apr 2014405421
May 2014565930
Jun 2014362721
Jul 2014585630
Aug 2014233020
Sep 2014463616
Oct 2014522723
Nov 2014463127
Dec 2014502916
Jan 2015343117
Feb 2015482420
Mar 2015493622
Apr 2015476229
May 2015555626
Jun 2015394930
Jul 2015355034
Aug 2015492919
Sep 2015322721
Oct 2015403214
Nov 2015434125
Dec 2015443125
Jan 2016593424
Feb 2016383112
Mar 2016433824
Apr 2016435236
May 2016466135
Jun 2016404024
Jul 2016403822
Aug 2016284721
Sep 2016444629
Oct 2016185014
Nov 2016283119
Dec 2016164520
Jan 2017165520
Feb 2017144715
Mar 2017204313
Apr 2017273732
May 2017165120
Jun 201785420
Jul 2017184521
Aug 2017128519
Sep 2017114418
Oct 2017176525
Nov 2017235423
Dec 2017184810
Jan 201884426
Feb 2018110118
Mar 201826017
Apr 201825221
May 201824514
Jun 201814315
Jul 201894127
Aug 201833618
Sep 2018133620
Oct 2018124517
Nov 2018114923
Dec 2018321213
Jan 201957105
Feb 201951187
Mar 20192575
Apr 20195052
May 20193466
Jun 20193169
Jul 2019161311
Aug 20192857
Sep 2019481011
Oct 20194604
Nov 20194221
Dec 2019281910
Jan 20201581
Feb 20205062
Mar 202010065
Apr 20208832
May 20203322
Jun 20202531
Jul 20202843
Aug 20202011
Sep 202034164
Oct 20205772
Nov 20204761
Dec 20205685
Jan 202141538
Feb 202140568
Mar 2021011

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 306 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 306, Issue 1
1 Jul 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

Bryan A. Ward, J. Christopher Gorski, David R. Jones, Stephen D. Hall, David A. Flockhart and Zeruesenay Desta
Journal of Pharmacology and Experimental Therapeutics July 1, 2003, 306 (1) 287-300; DOI: https://doi.org/10.1124/jpet.103.049601

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

Bryan A. Ward, J. Christopher Gorski, David R. Jones, Stephen D. Hall, David A. Flockhart and Zeruesenay Desta
Journal of Pharmacology and Experimental Therapeutics July 1, 2003, 306 (1) 287-300; DOI: https://doi.org/10.1124/jpet.103.049601
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Transport Is Not Rate-Limiting in Morphine Glucuronidation in the Single-Pass Perfused Rat Liver Preparation
  • Enhanced Hepatic Uptake and Bioactivity of Type α1(I) Collagen Gene Promoter-Specific Triplex-Forming Oligonucleotides after Conjugation with Cholesterol
  • Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
Show more ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics